|
1
|
Levy MM, Dellinger RP, Townsend SR,
Linde-Zwirble WT, Marshall JC, Bion J, Schorr C, Artigas A, Ramsay
G, Beale R, et al: The Surviving Sepsis Campaign: Results of an
international guideline-based performance improvement program
targeting severe sepsis. Intensive Care Med. 36:222–231. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ianaro A, Tersigni M and D'Acquisto F: New
insight in LPS antagonist. Mini Rev Med Chem. 9:306–317. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gioannini TL and Weiss JP: Regulation of
interactions of Gram-negative bacterial endotoxins with mammalian
cells. Immunol Res. 39:249–260. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marshall JC, Charbonney E and Gonzalez PD:
The immune system in critical illness. Clin Chest Med. 29:605–616.
vii2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Torgersen C, Moser P, Luckner G, Mayr V,
Jochberger S, Hasibeder WR and Dünser MW: Macroscopic postmortem
findings in 235 surgical intensive care patients with sepsis.
Anesth Analg. 108:1841–1847. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Opal SM, Laterre PF, Francois B, LaRosa
SP, Angus DC, Mira JP, Wittebole X, Dugernier T, Perrotin D,
Tidswell M, et al ACCESS Study Group: Effect of eritoran, an
antagonist of MD2-TLR4, on mortality in patients with severe
sepsis: The ACCESS randomized trial. JAMA. 309:1154–1162. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gonzalez-Rey E, Anderson P, González MA,
Rico L, Büscher D and Delgado M: Human adult stem cells derived
from adipose tissue protect against experimental colitis and
sepsis. Gut. 58:929–939. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee JW, Fang X, Gupta N, Serikov V and
Matthay MA: Allogeneic human mesenchymal stem cells for treatment
of E. coli endotoxin-induced acute lung injury in the ex vivo
perfused human lung. Proc Natl Acad Sci USA. 106:16357–16362. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Németh K, Leelahavanichkul A, Yuen PS,
Mayer B, Parmelee A, Doi K, Robey PG, Leelahavanichkul K, Koller
BH, Brown JM, et al: Bone marrow stromal cells attenuate sepsis via
prostaglandin E(2)-dependent reprogramming of host macrophages to
increase their interleukin-10 production. Nat Med. 15:42–49. 2009.
View Article : Google Scholar
|
|
10
|
Weil BR, Manukyan MC, Herrmann JL, Wang Y,
Abarbanell AM, Poynter JA and Meldrum DR: Mesenchymal stem cells
attenuate myocardial functional depression and reduce systemic and
myocardial inflammation during endotoxemia. Surgery. 148:444–452.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Weil BR, Herrmann JL, Abarbanell AM,
Manukyan MC, Poynter JA and Meldrum DR: Intravenous infusion of
mesenchymal stem cells is associated with improved myocardial
function during endotoxemia. Shock. 36:235–241. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Opal SM, Scannon PJ, Vincent JL, White M,
Carroll SF, Palardy JE, Parejo NA, Pribble JP and Lemke JH:
Relationship between plasma levels of lipopolysaccharide (LPS) and
LPS-binding protein in patients with severe sepsis and septic
shock. J Infect Dis. 180:1584–1589. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Marshall JC, Foster D, Vincent JL, Cook
DJ, Cohen J, Dellinger RP, Opal S, Abraham E, Brett SJ, Smith T, et
al: MEDIC study: Diagnostic and prognostic implications of
endotoxemia in critical illness: Results of the MEDIC study. J
Infect Dis. 190:527–534. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bone RC, Balk RA, Cerra FB, Dellinger RP,
Fein AM, Knaus WA, Schein RM and Sibbald WJ; The ACCP/SCCM
Consensus Conference Committee; American College of Chest
Physicians/Society of Critical Care Medicine: Definitions for
sepsis and organ failure and guidelines for the use of innovative
therapies in sepsis. Chest. 101:1644–1655. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hotchkiss RS and Karl IE: The
pathophysiology and treatment of sepsis. N Engl J Med. 348:138–150.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Medzhitov R: Approaching the asymptote: 20
years later. Immunity. 30:766–775. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tidswell M, Tillis W, Larosa SP, Lynn M,
Wittek AE, Kao R, Wheeler J and Gogate J; Opal SM; Eritoran Sepsis
Study Group: Phase 2 trial of eritoran tetrasodium (E5564), a
Toll-like receptor 4 antagonist, in patients with severe sepsis.
Crit Care Med. 38:72–83. 2010. View Article : Google Scholar
|
|
18
|
Hagar JA, Powell DA, Aachoui Y, Ernst RK
and Miao EA: Cytoplasmic LPS activates caspase-11: Implications in
TLR4-independent endotoxic shock. Science. 341:1250–1253. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kayagaki N, Wong MT, Stowe IB, Ramani SR,
Gonzalez LC, Akashi-Takamura S, Miyake K, Zhang J, Lee WP,
Muszyński A, et al: Noncanonical inflammasome activation by
intracellular LPS independent of TLR4. Science. 341:1246–1249.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ng TM and Monack DM: Revisiting caspase-11
function in host defense. Cell Host Microbe. 14:9–14. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lamkanfi M and Dixit VM: Inflammasomes:
Guardians of cytosolic sanctity. Immunol Rev. 227:95–105. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tang BM, Huang SJ and McLean AS:
Genome-wide transcription profiling of human sepsis: A systematic
review. Crit Care. 14:R2372010. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Monneret G, Venet F, Pachot A and Lepape
A: Monitoring immune dysfunctions in the septic patient: A new skin
for the old ceremony. Mol Med. 14:64–78. 2008. View Article : Google Scholar
|
|
24
|
Skrupky LP, Kerby PW and Hotchkiss RS:
Advances in the management of sepsis and the understanding of key
immunologic defects. Anesthesiology. 115:1349–1362. 2011.PubMed/NCBI
|
|
25
|
Salomao R, Brunialti MK, Rapozo MM,
Baggio-Zappia GL, Galanos C and Freudenberg M: Bacterial sensing,
cell signaling, and modulation of the immune response during
sepsis. Shock. 38:227–242. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hotchkiss RS and Opal S: Immunotherapy for
sepsis - a new approach against an ancient foe. N Engl J Med.
363:87–89. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Beyth S, Borovsky Z, Mevorach D,
Liebergall M, Gazit Z, Aslan H, Galun E and Rachmilewitz J: Human
mesenchymal stem cells alter antigen-presenting cell maturation and
induce T-cell unresponsiveness. Blood. 105:2214–2219. 2005.
View Article : Google Scholar
|
|
28
|
Aggarwal S and Pittenger MF: Human
mesenchymal stem cells modulate allogeneic immune cell responses.
Blood. 105:1815–1822. 2005. View Article : Google Scholar
|
|
29
|
Ramasamy R, Fazekasova H, Lam EW, Soeiro
I, Lombardi G and Dazzi F: Mesenchymal stem cells inhibit dendritic
cell differentiation and function by preventing entry into the cell
cycle. Transplantation. 83:71–76. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stagg J: Immune regulation by mesenchymal
stem cells: Two sides to the coin. Tissue Antigens. 69:1–9. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chan JL, Tang KC, Patel AP, Bonilla LM,
Pierobon N, Ponzio NM and Rameshwar P: Antigen-presenting property
of mesenchymal stem cells occurs during a narrow window at low
levels of interferon-gamma. Blood. 107:4817–4824. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Traggiai E, Volpi S, Schena F, Gattorno M,
Ferlito F, Moretta L and Martini A: Bone marrow-derived mesenchymal
stem cells induce both polyclonal expansion and differentiation of
B cells isolated from healthy donors and systemic lupus
erythematosus patients. Stem Cells. 26:562–569. 2008. View Article : Google Scholar
|
|
33
|
Shin S, Kim Y, Jeong S, Hong S, Kim I, Lee
W and Choi S: The therapeutic effect of human adult stem cells
derived from adipose tissue in endotoxemic rat model. Int J Med
Sci. 10:8–18. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mei SH, Haitsma JJ, Dos Santos CC, Deng Y,
Lai PF, Slutsky AS, Liles WC and Stewart DJ: Mesenchymal stem cells
reduce inflammation while enhancing bacterial clearance and
improving survival in sepsis. Am J Respir Crit Care Med.
182:1047–1057. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
van Dissel JT, van Langevelde P,
Westendorp RG, Kwappenberg K and Frölich M: Anti-inflammatory
cytokine profile and mortality in febrile patients. Lancet.
351:950–953. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Krasnodembskaya A, Song Y, Fang X, Gupta
N, Serikov V, Lee JW and Matthay MA: Antibacterial effect of human
mesenchymal stem cells is mediated in part from secretion of the
antimicrobial peptide LL-37. Stem Cells. 28:2229–2238. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hall SR, Tsoyi K, Ith B, Padera RF Jr,
Lederer JA, Wang Z, Liu X and Perrella MA: Mesenchymal stromal
cells improve survival during sepsis in the absence of heme
oxygenase-1: the importance of neutrophils. Stem Cells. 31:397–407.
2013. View Article : Google Scholar :
|
